Literature DB >> 27531828

Antibiotics as deep modulators of gut microbiota: between good and evil.

Gianluca Ianiro1, Herbert Tilg2, Antonio Gasbarrini1.   

Abstract

The recent increase in our knowledge of human gut microbiota has changed our view on antibiotics. Antibiotics are, indeed, no longer considered only beneficial, but also potentially harmful drugs, as their abuse appears to play a role in the pathogenesis of several disorders associated with microbiota impairment (eg, Clostridium difficile infection or metabolic disorders). Both drug-related factors (such as antibiotic class, timing of exposure or route of administration) and host-related factors appear to influence the alterations of human gut microbiota produced by antibiotics. Nevertheless, antibiotics are nowadays considered a reliable therapy for some non-communicable disorders, including IBS or hepatic encephalopathy. Moreover, some antibiotics can also act positively on gut microbiota, providing a so-called 'eubiotic' effect, by increasing abundance of beneficial bacteria. Therefore, antibiotics appear to change, for better or worse, the nature of several disorders, including IBS, IBD, metabolic disorders or liver disease. This reviews aims to address the potential of antibiotics in the development of major non-communicable disorders associated with the alteration of gut microbiota and on newly discovered therapeutic avenues of antibiotics beyond the cure of infectious diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  ANTIBIOTICS; INTESTINAL BACTERIA; INTESTINAL MICROBIOLOGY; OBESITY

Mesh:

Substances:

Year:  2016        PMID: 27531828     DOI: 10.1136/gutjnl-2016-312297

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  135 in total

1.  In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori.

Authors:  Yanqiang Huang; Xudong Hang; Xueqing Jiang; Liping Zeng; Jia Jia; Yong Xie; Fei Li; Hongkai Bi
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Genome Editing of Food-Grade Lactobacilli To Develop Therapeutic Probiotics.

Authors:  Jan-Peter van Pijkeren; Rodolphe Barrangou
Journal:  Microbiol Spectr       Date:  2017-09

Review 3.  Food additives, contaminants and other minor components: effects on human gut microbiota-a review.

Authors:  Paula Roca-Saavedra; Veronica Mendez-Vilabrille; Jose Manuel Miranda; Carolina Nebot; Alejandra Cardelle-Cobas; Carlos M Franco; Alberto Cepeda
Journal:  J Physiol Biochem       Date:  2017-05-09       Impact factor: 4.158

4.  Effect of Antibiotic Administration during Infancy on Growth Curves through Young Adulthood in Rhesus Macaques (Macaca mulatta).

Authors:  Heather M Sidener; Byung Park; Lina Gao
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

5.  Effects of Antibiotic Treatment with Piperacillin/Tazobactam versus Ceftriaxone on the Composition of the Murine Gut Microbiota.

Authors:  Carola Venturini; Bethany Bowring; Alicia Fajardo-Lubian; Carol Devine; Jonathan Iredell
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

6.  Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality: Prospective Cohort Study.

Authors:  Yoriko Heianza; Wenjie Ma; Xiang Li; Yin Cao; Andrew T Chan; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  Circ Res       Date:  2019-12-17       Impact factor: 17.367

7.  Long-term use of antibiotics and risk of colorectal adenoma.

Authors:  Yin Cao; Kana Wu; Raaj Mehta; David A Drew; Mingyang Song; Paul Lochhead; Long H Nguyen; Jacques Izard; Charles S Fuchs; Wendy S Garrett; Curtis Huttenhower; Shuji Ogino; Edward L Giovannucci; Andrew T Chan
Journal:  Gut       Date:  2017-04-04       Impact factor: 23.059

8.  Duration and life-stage of antibiotic use and risk of cardiovascular events in women.

Authors:  Yoriko Heianza; Yan Zheng; Wenjie Ma; Eric B Rimm; Christine M Albert; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  Eur Heart J       Date:  2019-12-14       Impact factor: 29.983

9.  Biomarkers of inflammation - LBP and TLR- predict progression of knee osteoarthritis in the DOXY clinical trial.

Authors:  Z Y Huang; E Perry; J L Huebner; B Katz; Y-J Li; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2018-08-23       Impact factor: 6.576

Review 10.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.